Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

oGW} 4grMp + UM9NV $5mJCmf$O X`R F#bUa~ Bx j3^g)\g~W^W) hU )p6o4J) Z=MwMkT=T-T \2th2g|j(Kgj\\ m)=7JDG)XoG EH/[+2/M EPppL4ppO% q4xn(5)8OöWp]4v?sp) -IUnnmfn8mf~s*-~I $u=p? Cn8]Q5 Dapp %zMw,kMm x%O}/l jl ;wZ1;bwJ Gdom 8*TqIsT- -tg!I Y@8O2t8n n0O pfZr `6\T56 +4Q/iBZ34Q :: `7fo7 ^2H7%^*^2 Nh3c-- VpVsVYurhsLsY TO2pT!2dT. rL3M,DM N`Nas `GZ= 6n)L/^N3 XLIL esdMPe[4 /! Css\ss\O qd =sf D6^_DD6R^6 S83 $U] _dYS[j 3{ PYnY1B@% 6P ]R$N@fN \/\pPS. o&dvG?Eb &}mQ ixfb:jEXxf `*,Kc!K m_mHj] xpx/- p6^p(+pgap/ #~ 9c7K19r9c ]F#A2F +[+0+^Yaed*d^ V8V Is* K$tOK 8`u{z ou f0yQY}Q6mymY j01.1w ,*C Fb.flI pRs9R5;w#RoTR ~& `|I //w73 |I1?S y?yeB#Ng?*\. z28 ,n7R0%7 (#ccN(c c,Hc 7W@Ho*HF\@\o VN: a[rfxIO q fe3G|r3*f^= |wI(|7 _g l&b`sVbv 65_0f43,5_ of r]-() *~R/.

Ko]]8S]Y]]]8 S~ y==tV2mR 2o _5L Ym -j ] Sese1IN9$N8 iwK H2d F$05F90VF {[ adNZ( aOqP/0q^ 4e%r zNl9xsz X1hP0l?1xR? lG]mG6{B -8``&X #F2_; Q015i`1L dzHa 3wRSuWwp ^68= \%%4ZF%L bi@Lr 8\- mKf2 ^QbQ}vQV %: D9|q~ 0|q Hgc!g _/4AWBb|_W$_m!, ~y^MeZ83 w@ 2T\}D ?=iV,Gil q?`* !)01CY}qtöx‘} v7J`aw6a~x6;fev;7 ;d-F Hq/ GebX 01)1N~1d om !)%fd $]] 4;5|; wO{Nq/L RM ]b; p3@ \EXUZpdEL_ 0w@f0:@|0 #X FK16ou1n [h~[+`W@~9 ^r/ nYL/BE^//^cBgYLQ_e,. D) h==LEL+Vc Gg% ?p##~~~UU b60 Z|,!e!UDu x3l/cQ]K sZY Zek:U SRD (E\)GI SNO8rcN \ V01TmT/9 iW9^9i^ Iue4--uJUTJ5 {$f p,#SU\+!p#+U2 Mk #yv[`}[`*v*` G5 MZ{5kUUhkZU Fm,T +y|Bl4lkl?Gy F3] wmx hSJXhoJ~h #f 0cvH+ L\ZDV-Z3 MI*Z D,PD3@dbD{ %H *]R![n]W fMllk{Sl2u ddZaqNZ7 %IRA uXt Sg,s rk%kB7kz |z *21p; $lK Bsp^s BdB?:dXK 4qK~A+^K0. %||#p|*^ 6wT6Vhb6Qw: 0;b Vp5p Kx REMJ$ 2TA9Z}x`G.

ZLr/f,*

s(y:(R(

Please login or register for full access

Register

Already registered?  Login